🇺🇸 FDA
Pipeline program

Experimental: CHF6001 3200 μg

CLI-06001AA2-01

Phase 2 small_molecule terminated

Quick answer

Experimental: CHF6001 3200 μg for Uncontrolled Asthma is a Phase 2 program (small_molecule) at Chiesi Farmaceutici S.p.A. with 1 ClinicalTrials.gov record(s).

Program details

Company
Chiesi Farmaceutici S.p.A.
Indication
Uncontrolled Asthma
Phase
Phase 2
Modality
small_molecule
Status
terminated

Clinical trials